Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Targeted ImmunoPET Scan Detects Multiple Myeloma Missed by Standard PET/CT

By HospiMedica International staff writers
Posted on 06 Nov 2026

Multiple myeloma is a blood cancer that develops in the bone marrow and can affect multiple sites throughout the body. More...

Standard imaging and blood tests may miss areas of active disease, potentially complicating diagnosis, treatment selection, and post-treatment assessment. This is particularly important when residual disease persists despite otherwise negative findings. Researchers have now developed a targeted immuno-positron emission tomography scan designed to detect myeloma that may be missed by standard testing.

The phase 2 clinical trial was led by Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. The technology, known as immunoPET, uses radiolabeled antibodies that bind directly to myeloma cells. The study specifically evaluated ⁸⁹Zr-daratumumab for CD38-targeted immunoPET, which targets CD38, a surface protein expressed on myeloma cells.

Current standard-of-care monitoring often relies on positron emission tomography/computed tomography (PET/CT) using radiolabeled glucose. These scans detect areas where tumor cells take up more glucose than surrounding tissue. In multiple myeloma, however, this pattern is not always reliable, and standard PET/CT can miss residual disease in up to 40% of cases when abnormal glucose uptake is absent.

Researchers first evaluated the antibody-based approach in laboratory models with collaborators at Hoag Cancer Center before advancing it into early human studies and a multicenter phase 2 clinical trial. The trial enrolled 60 patients with multiple myeloma who underwent both standard glucose-based PET/CT and immunoPET.

More than 10% of patients had disease signals detected only by immunoPET, and follow-up biopsies confirmed that these findings represented active myeloma missed by standard PET/CT. Overall, immunoPET identified disease that standard PET/CT missed in 17 patients, or 28%, while standard PET/CT detected disease missed by immunoPET in 13 patients, or 22%. The two scans showed similar disease burden in the remaining patients, indicating that neither imaging approach detected every case.

The study was published in Radiology on November 3, 2026. A practical limitation of the current approach is that the antibody takes about one week to circulate through the body and bind to cancer cells. Researchers are therefore developing next-generation versions using smaller antibody fragments that could reach tumors more quickly and potentially enable same-day imaging.

“If we are going to cure multiple myeloma, we need two things. One, we need really effective medicines. Second, we need to be able to make sure there is no disease left behind after these treatments. We are developing new and better technology designed to see where the disease is and make sure we are not missing it,” said C. Ola Landgren, M.D., Ph.D., chief of the Myeloma Division, director of Sylvester Myeloma Institute and senior author of the study.

Related Links
Sylvester Comprehensive Cancer Center


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Hybrid Arch Device
Neo EDE
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image Credit: Shutterstock

Explainable AI Examines Sepsis Mortality Risk and Emergency Care Delays

Preventing sepsis-related deaths in emergency departments (EDs) remains challenging because patient deterioration can result from multiple rapidly evolving and interconnected factors. These include triage... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Health IT

view channel
Image Credit: Shutterstock

Telemonitoring Program Improves Quality of Life After Heart Failure Discharge

Heart failure is a chronic condition associated with high mortality, frequent hospitalizations, and reduced quality of life. Patients face particularly high risks of readmission and death after discharge,... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.